Alizyme plc (LSE:AZM) is pleased to announce the preliminary results of its successful Phase IIb clinical trial of cetilistat in clinically obese diabetic patients.
Alizyme plc (LSE:AZM) is pleased to announce the preliminary results of its successful Phase IIb clinical trial of cetilistat in clinically obese diabetic patients.